Skip to Content

iShares Biotechnology ETF IBB ETF Analysis

| Quantitative rating as of | See iShares Investment Hub

Morningstar’s Analysis IBB

Will IBB outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.



Increased confidence in iShares Biotechnology ETF's prospects relative to its Morningstar Category peers leads to an upgrade in this strategy's Morningstar Quantitative Rating to Neutral from Negative. The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Unlock our full analysis with Morningstar Investor